The Department of Genetic Medicine at Weill Cornell Medicine would like to invite you to learn more about a gene therapy trial for individuals who are ApoE4/E4 and diagnosed with mild cognitive impairment (MCI) or Alzheimer’s disease (AD). The gene therapy is comprised of an adeno-associated virus gene transfer vector coding for ApoE2 which will be delivered intracisternally. The E2 allele is the rarest form of ApoE and carrying even one copy appears to reduce the risk of developing Alzheimer’s by up to 40%. The goal of the trial is to add the ApoE2 gene into the central nervous system to compensate for the effects of ApoE4, and thus prevent or delay the progression of AD.
The trial takes place in New York City and consists of an initial examination, the gene therapy administration and multiple follow-up visits over the course of a year. The initial examination will determine an individual’s eligibility to receive the gene therapy and includes a PET scan, an MRI scan and a spinal tap. For more information and a short video.
If you would like to learn more about the trial, contact Denesy Mancenido at: dem2026@med.cornell.edu.